Celldex Therapeutics Stock Forecast, Price & News

Celldex Therapeutics (NASDAQ:CLDX) Frequently Asked Questions

Is Celldex Therapeutics a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Celldex Therapeutics stock.
View analyst ratings for Celldex Therapeutics or view top-rated stocks.

How has Celldex Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Celldex Therapeutics' stock was trading at $2.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CLDX stock has increased by 1,752.7% and is now trading at $37.61.
View which stocks have been most impacted by COVID-19.

Are investors shorting Celldex Therapeutics?

Celldex Therapeutics saw a increase in short interest during the month of October. As of October 29th, there was short interest totaling 3,720,000 shares, an increase of 25.7% from the October 14th total of 2,960,000 shares. Based on an average trading volume of 472,500 shares, the short-interest ratio is currently 7.9 days.
View Celldex Therapeutics' Short Interest.

When is Celldex Therapeutics' next earnings date?

Celldex Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, April 4th 2022.
View our earnings forecast for Celldex Therapeutics.

How were Celldex Therapeutics' earnings last quarter?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) issued its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.36) by $0.09. The biopharmaceutical company earned $0.15 million during the quarter, compared to analyst estimates of $1.70 million. Celldex Therapeutics had a negative net margin of 891.70% and a negative trailing twelve-month return on equity of 22.71%.
View Celldex Therapeutics' earnings history.

When did Celldex Therapeutics' stock split? How did Celldex Therapeutics' stock split work?

Shares of Celldex Therapeutics reverse split on the morning of Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 8th 2019. An investor that had 100 shares of Celldex Therapeutics stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for CLDX?

5 brokers have issued 1-year price targets for Celldex Therapeutics' stock. Their forecasts range from $35.00 to $68.00. On average, they anticipate Celldex Therapeutics' share price to reach $59.00 in the next twelve months. This suggests a possible upside of 56.9% from the stock's current price.
View analysts' price targets for Celldex Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Celldex Therapeutics' key executives?

Celldex Therapeutics' management team includes the following people:

• Anthony S. Marucci, President, Chief Executive Officer & Director
• Sam Martin, CFO, Secretary, Treasurer & Senior Vice President
• Tibor Keler, Chief Scientific Officer & Executive VP
• Diane C. Young, Chief Medical Officer & Senior Vice President (LinkedIn Profile)
• Elizabeth Crowley, Chief Product Development Officer & Senior VP

Who are some of Celldex Therapeutics' key competitors?

Some companies that are related to Celldex Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Incyte (INCY), Exact Sciences (EXAS), Novavax (NVAX), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX) and Exelixis (EXEL).
View all of CLDX's competitors.

What other stocks do shareholders of Celldex Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include OPKO Health (OPK), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP), Precigen (PGEN), Micron Technology (MU), Dynavax Technologies (DVAX), Exelixis (EXEL), bluebird bio (BLUE) and SCYNEXIS (SCYX).

What is Celldex Therapeutics' stock symbol?

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

Who are Celldex Therapeutics' major shareholders?

Celldex Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.74%), Wellington Management Group LLP (4.67%), RA Capital Management L.P. (3.43%), VR Adviser LLC (2.35%), Geode Capital Management LLC (1.70%) and Viking Global Investors LP (1.63%). Company insiders that own Celldex Therapeutics stock include Anthony S Marucci, Diane C Young, Freddy A Jimenez, James J Marino, Margo Heath-Chiozzi, Richard M Wright, Samuel Bates Martin and Tibor Keler.
View institutional ownership trends for Celldex Therapeutics.

Which major investors are selling Celldex Therapeutics stock?

CLDX stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Renaissance Technologies LLC, VR Adviser LLC, Allianz Asset Management GmbH, Commodore Capital LP, TSP Capital Management Group LLC, AXA S.A., and Goldman Sachs Group Inc.. Company insiders that have sold Celldex Therapeutics company stock in the last year include Diane C Young, Richard M Wright, and Samuel Bates Martin.
View insider buying and selling activity for Celldex Therapeutics or view top insider-selling stocks.

Which major investors are buying Celldex Therapeutics stock?

CLDX stock was purchased by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Viking Global Investors LP, Cowen AND Company LLC, BlackRock Inc., Polar Capital Holdings Plc, Wellington Management Group LLP, Sphera Funds Management LTD., and Geode Capital Management LLC. Company insiders that have bought Celldex Therapeutics stock in the last two years include Anthony S Marucci, Diane C Young, Freddy A Jimenez, James J Marino, Margo Heath-Chiozzi, Samuel Bates Martin, and Tibor Keler.
View insider buying and selling activity for Celldex Therapeutics or or view top insider-buying stocks.

How do I buy shares of Celldex Therapeutics?

Shares of CLDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Celldex Therapeutics' stock price today?

One share of CLDX stock can currently be purchased for approximately $37.61.

How much money does Celldex Therapeutics make?

Celldex Therapeutics has a market capitalization of $1.76 billion and generates $7.42 million in revenue each year. The biopharmaceutical company earns $-59.78 million in net income (profit) each year or ($1.76) on an earnings per share basis.

How many employees does Celldex Therapeutics have?

Celldex Therapeutics employs 124 workers across the globe.

When was Celldex Therapeutics founded?

Celldex Therapeutics was founded in 1983.

What is Celldex Therapeutics' official website?

The official website for Celldex Therapeutics is www.celldex.com.

Where are Celldex Therapeutics' headquarters?

Celldex Therapeutics is headquartered at 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827.

How can I contact Celldex Therapeutics?

Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The biopharmaceutical company can be reached via phone at (908) 200-7500, via email at [email protected], or via fax at 908-454-1911.